Tvardi Therapeutics (TVRD) Net Income towards Common Stockholders: 2012-2016
Historic Net Income towards Common Stockholders for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2016 value amounting to -$57.3 million.
- Tvardi Therapeutics' Net Income towards Common Stockholders fell 7.81% to -$12.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$65.9 million, marking a year-over-year decrease of 47.01%. This contributed to the annual value of -$57.3 million for FY2016, which is 132.00% down from last year.
- Per Tvardi Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$57.3 million for FY2016, which was down 132.00% from -$24.7 million recorded in FY2015.
- Tvardi Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$4.0 million during FY2013, with a 5-year trough of -$57.3 million in FY2016.
- Its 3-year average for Net Income towards Common Stockholders is -$33.2 million, with a median of -$24.7 million in 2015.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 36.80% in 2013, then slumped by 347.77% in 2014.
- Over the past 5 years, Tvardi Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$6.3 million in 2012, then surged by 36.80% to -$4.0 million in 2013, then crashed by 347.77% to -$17.7 million in 2014, then plummeted by 39.14% to -$24.7 million in 2015, then plummeted by 132.00% to -$57.3 million in 2016.